Recent developments include the company’s initial public offering in December 2024 raising $4.8 million and a follow-on public offering in January 2026 raising $2.45 million. The company also changed its ticker symbol to BYAH in October 2025 and experienced a director resignation in March 2026.

• Park Ha Biological Technology Co., Ltd. closed its initial public offering on December 30, 2024, raising $4.8 million on Nasdaq [N2].
• On January 28, 2026, the company closed a follow-on public offering raising $2.45 million, with stock price declining following the offering [N1].
• The company changed its trading symbol from PHH to BYAH effective October 28, 2025, aiming to enhance brand influence [S1].
• Ms. Li Wang resigned as a director effective March 16, 2026, with no disagreement with company operations reported [S2].

The company’s focus on innovation in skincare technology, particularly in hydration penetration, and its expansion of franchise and retail operations in multiple Chinese provinces could support growth in customer base and revenues. Recent capital raises through IPO and follow-on offerings provide financial resources to invest in R&D, marketing, and supply chain capacity. The management team’s industry experience and commitment to brand building and customer service may enhance competitive positioning. Expansion of training programs and social media marketing could strengthen franchisee capabilities and brand awareness.

Park Ha Biological faces significant risks from regulatory uncertainties and government intervention in China, which could impact its operations and ability to transfer funds. The company’s financial performance shows a substantial net loss and increased administrative expenses, including large share-based payments, which may pressure liquidity and profitability. Reliance on a limited number of suppliers and customers exposes the company to supply chain and revenue concentration risks. Competition from larger, established brands with economies of scale may limit market penetration. The variable interest entity structure used for PRC subsidiaries carries legal and enforcement risks. Volatility in stock price and governance risks related to concentrated control by the CEO are additional concerns.

Park Ha Biological’s moat is based on its integrated approach combining proprietary skincare product development, a franchising business model, and targeted marketing to urban female consumers in China. The company’s collaborations with scientific research institutions and focus on innovation in hydration technology provide product differentiation. Its established supplier relationships and quality control processes support product reliability. The franchising model enables geographic expansion with lower capital intensity. However, the company faces competition from larger, more established domestic and multinational brands with greater scale and brand recognition, which may limit its market share growth and pricing power.

• Regulatory and Political Risks in China: The company operates through PRC subsidiaries subject to evolving laws, regulations, and government oversight. Restrictions on cash transfers, approvals for securities offerings, and potential government intervention could materially affect operations and investor returns.
• Financial Performance and Liquidity Risks: The company reported a significant net loss of $24.36 million for fiscal 2025 and increased general and administrative expenses largely due to share-based payments. Operating cash flow decreased compared to prior year, which may impact ability to fund operations and expansion.
• Supplier and Customer Concentration: The company relies on a limited number of suppliers for raw materials and a few major customers for revenue. Disruptions in supply or loss of key customers could materially affect business results.
• Competitive Market Environment: The beauty industry is highly competitive with established multinational and domestic brands. The company may face challenges in gaining market share and maintaining profitability due to pricing pressures and brand recognition.
• Variable Interest Entity Structure Risks: The use of VIE agreements to operate PRC subsidiaries carries risks related to contract enforceability, regulatory scrutiny, and potential loss of consolidated reporting, which could impact reported financials and operations.

• Park Ha Biological Technology Co., Ltd. operates primarily in the beauty and skincare industry in China through its PRC subsidiaries, focusing on skincare products and franchise operations.
• The company develops and sells functional skincare products, collaborating with biological laboratories and supply chain partners to transform technology into cost-effective products.
• The product line includes skin physical protection, exfoliation, sebum film repairing, and hydration products, with plans to develop small molecule peptide hydration penetration technology.
• The company operates both directly owned stores and franchise stores, mostly located in first-, second-, and third-tier cities across various Chinese provinces including Jiangsu, Shanxi, Shandong, Liaoning, Heilongjiang, and Hebei.
• As of October 31, 2025, the company had about 6,630 retail customers in directly operated stores, primarily targeting young adult and middle-aged women with white-collar occupations living or working near business districts.
• The company relies on a limited number of suppliers for raw materials, with two suppliers accounting for approximately 26% and 11% of total purchases in fiscal 2025.
• Revenue for fiscal year ended October 31, 2025 was $2.52 million, with a net loss of $24.36 million and basic and diluted EPS of -$41.38 per share.
• Cash and cash equivalents as of October 31, 2025 were $3.79 million, with current assets of $5.5 million and current liabilities of $1.88 million, resulting in a current ratio of 2.92 and cash ratio of 2.01.
• The company’s general and administrative expenses increased significantly in fiscal 2025 due to share-based payment expenses and professional fees related to listing and investor relations.
• Franchise fees revenue decreased by 10% from fiscal 2024 to 2025, while product sales revenue increased by 43% in the same period.
• The company completed an initial public offering raising $4.8 million on Nasdaq in December 2024 and a follow-on public offering raising $2.45 million in January 2026.
• The company faces risks related to doing business in China, including regulatory uncertainties, restrictions on cash transfers, government intervention, and evolving legal and regulatory environment.
• Other risks include reliance on a limited number of suppliers and customers, competition in the beauty industry, and risks related to the variable interest entity structure used for its PRC subsidiaries.
• The company’s CEO and Chairperson, Ms. Xiaoqiu Zhang, has significant influence over corporate decisions.
• The company has a policy of terminating cooperation with partners that do not meet quality standards and conducts supplier visits and factory inspections to ensure quality.
• The company plans to expand R&D partnerships, enhance training practices, improve social media marketing, and seek strategic investments and acquisitions to support growth.
• The company’s liquidity position as of October 31, 2025 is supported by cash and current assets exceeding current liabilities, but operating cash flow decreased compared to prior year.
• The company’s business model includes franchising, product sales, and training services, with a focus on brand building and geographic expansion within China.
• The company’s shares changed ticker symbol from PHH to BYAH effective October 28, 2025.
• The company carries director and officer insurance but does not maintain insurance for assets or business interruption losses.